Waystar Holding (WAY) Earnings Call Presentation

Acquisition Overview - Waystar is set to acquire Iodine Software for a total enterprise value of $1.25 billion [7] - Iodine shareholders will own approximately 8% of Waystar on a fully diluted, pro forma basis [9] - Advent, Iodine's largest shareholder, is expected to receive 100% of its transaction consideration in Waystar common stock [9] Strategic Rationale - The acquisition aims to simplify healthcare payments and accelerate AI-powered transformation [5] - It expands Waystar's total addressable market by more than 15% [5] - The deal integrates clinical intelligence software to prevent denials and ensure optimal reimbursement [5] Financial Impact - Iodine's profile includes approximately 99% revenue derived from software subscriptions [26] - Iodine's gross margin is approximately 75% [26] - Iodine's Adjusted EBITDA margin is approximately 40% [26] Q2 2025 Preliminary Results - Waystar's approximate Q2 2025 revenue is $271 million [31] - Waystar's approximate year-over-year growth is 15% [32]